Respiratory muscle endurance training	Baseline characteristics	Improvement in myasthenia score	1039	1107	Myasthenia score improved from 0.71 ± 0.1 to 0.56 ± 0.1 (P = 0.007).
Respiratory muscle endurance training	Baseline characteristics	Lung function parameters	13635	13941	RMET induced mild but not significant increases in VC (P1: 95.9 ± 3.5%, P4: 99.2 ± 4.1%, P = 0.39), FEV1 (P1: 93.1 ± 2.7%, P4: 96.3 ± 3.8%, P = 0.28), PEF (P1: 90.0 ± 4.8%, P4: 95.7 ± 5.4%, P = 0.07), MVV (P1: 95.6 ± 6.0%, P4: 101.0 ± 6.5%, P = 0.24), and PImax (P1: 79.2 ± 5.4%, P4: 78.0 ± 6.4%, P = 0.42)
Respiratory muscle endurance training	Baseline characteristics	Improvement in respiratory endurance	1108	1190	Respiratory endurance time increased from 6.1 ± 0.8 to 20.3 ± 3.0 min (P < 0.001).
Respiratory muscle endurance training	Baseline characteristics	Improvement in respiratory endurance	1108	1189	Respiratory endurance time increased from 6.1 ± 0.8 to 20.3 ± 3.0 min (P < 0.001)
Respiratory muscle endurance training	Baseline characteristics	Lung function parameters	13441	13942	Baseline lung function was normal for all patients with VC being 95.5 ± 3.7%, FEV1 90.5 ± 3.6%, PEF 86.9 ± 4.5%, MVV 93.8 ± 6.6%, and maximal inspiratory pressure (PImax) 75.1 ± 5.4% predicted. RMET induced mild but not significant increases in VC (P1: 95.9 ± 3.5%, P4: 99.2 ± 4.1%, P = 0.39), FEV1 (P1: 93.1 ± 2.7%, P4: 96.3 ± 3.8%, P = 0.28), PEF (P1: 90.0 ± 4.8%, P4: 95.7 ± 5.4%, P = 0.07), MVV (P1: 95.6 ± 6.0%, P4: 101.0 ± 6.5%, P = 0.24), and PImax (P1: 79.2 ± 5.4%, P4: 78.0 ± 6.4%, P = 0.42).
